Full-Time
Digital Marketing Manager
Updated on 9/3/2026
Ansa Biotechnologies
51-200 employees
Enzymatic DNA synthesis as a service
Compensation Overview
$145k - $160k/yr
Oakland, CA, USA
Hybrid
Hybrid role in Emeryville, California; preference for local Bay Area candidates.
Bachelor's
 Growth & Marketing (1) |
|---|
Get referred to Ansa Biotechnologies
See people who can refer or advise you
- Bachelor’s degree in marketing, communications, or a creative discipline
- 3+ years of relevant experience in digital marketing
- Strong proficiency in HubSpot
- Experience in SEM, SEO, and Google Analytics
- Working in close collaboration with the Director of Marketing, develop and execute comprehensive digital marketing strategies to drive awareness, lead generation, and customer retention in line with company goals.
- Own the marketing automation platform (HubSpot) including campaign setup and execution to manage end-to-end digital campaigns including PPC, paid social, and email.
- Manage the execution of lead data management, ensuring high-quality, well-structured segmentation (e.g., application, industry) to unlock scalable, data-driven targeting and maximize campaign effectiveness.
- Design and implement A/B testing strategies to improve campaign performance and conversion rates.
- Experience with Salesforce to track lead status, review lead funnel progress, and maintain data integrity in collaboration with the Director of Comm Ops.
- Ensure all campaigns adhere to approved strategic briefs, maintain brand consistency, and leverage AI driven tools to optimize performance and personalization.
- Use data-driven insights to analyze KPIs, including traffic, engagement, conversion rates, and ROI.
- Evaluate and pilot emerging digital channels, platforms, and tactics to expand reach and drive incremental growth.
- Strong preference for experience in healthcare or life science industries
- Preference for local Bay Area location
Ansa Biotechnologies provides DNA synthesis as a service. It uses a proprietary enzymatic DNA synthesis method to make long, gene-length DNA sequences directly, bypassing the bottlenecks of traditional chemical methods. Customers—mainly researchers in healthcare, agriculture, and industrial biotechnology—order specific DNA sequences and pay for the synthesized DNA. The technology works by assembling DNA with enzymes rather than chemical steps, enabling longer molecules to be produced more quickly and reliably. This sets Ansa Biotechnologies apart from competitors that rely on older synthesis methods that struggle with long sequences, offering a more scalable way to access gene-length DNA. The goal is to speed scientific progress by making high-quality long DNA sequences available for research, development, and application in medicines, crops, and biotech products.
Company Size
51-200
Company Stage
Series B
Total Funding
$137M
Headquarters
Emeryville, California
Founded
2018
Get referred to Ansa Biotechnologies
See people who can refer or advise you
Simplify's Take
What believers are saying
- Axio BioPharma named Ansa preferred provider on August 24, 2026, expanding antibody workflow demand.
- Ansa appointed COO Matthias Arenskötter on March 31, 2026 to scale operations.
- The August 2026 press cycle shows active commercialization, hiring, and customer validation across biopharma.
What critics are saying
- Danaher-owned IDT can commoditize Ansa’s premium niche and pressure pricing by 2027.
- Headcount fell to 75 employees by March 2026, limiting manufacturing resilience during demand spikes.
- If 50 kb quality slips, the on-time guarantee turns into margin-destroying free shipments.
What makes Ansa Biotechnologies unique
- Ansa delivers sequence-perfect clonal DNA up to 50 kb, beyond legacy 10 kb limits.
- Its enzymatic synthesis avoids harsh chemicals, improving length, complexity, and turnaround predictability.
- The January 2026 IDT collaboration puts Ansa inside Danaher’s global synthetic biology distribution.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Company Equity
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -6%2 year growth
↓ -6%Axio BioPharma selects Ansa Biotechnologies as preferred gene synthesis provider. Preferred partnership helps strengthen high-throughput antibody production workflows by reducing schedule risk and improving delivery predictability MADISON, WI, UNITED STATES, August 24, 2026 / EINPresswire.com / - Axio BioPharma, a vendor-neutral data infrastructure company for biomanufacturing, today named Ansa Biotechnologies, the trusted partner in DNA synthesis, as its preferred gene synthesis provider. Axio Forge, the company's high-throughput non-GMP monoclonal antibody laboratory, already routes gene synthesis to Ansa across its production workflows. Forge delivers purified antibodies on a 3-5 week turnaround from electronic sequence, with a fee-for-service model. Gene synthesis is the first step in every antibody production program, so a delay there holds back every downstream activity, from expression and purification through characterization and delivery. Routing that work to Ansa removes one of the earliest sources of schedule risk in the Forge workflow. Ansa's proprietary synthesis platform provides the length, complexity, and scalability required to design and manufacture even the most demanding DNA constructs. The Ansa On-Time Guarantee ensures complete orders are shipped by the committed date or they are free of charge. Manufactured exclusively in the United States, Ansa's products integrate seamlessly into existing workflows to accelerate the next wave of biological discovery. Ansa operates under a rigorous biosecurity framework and is fully compliant with the U.S. Office of Science and Technology Policy Framework for Nucleic Acid Synthesis Screening. "Customers don't measure success by how quickly we can move on our best day. They measure it by whether we deliver when we said we would," said Justin Byers, Founder and Chief Executive Officer of Axio BioPharma. "Gene synthesis is one of the earliest steps in antibody production, but it often determines whether an entire program stays on schedule. Working with Ansa gives us greater confidence that the timelines we commit to our customers are timelines we can consistently deliver, including for the complex constructs that have traditionally created the greatest uncertainty." The collaboration reflects Axio BioPharma's broader strategy of building an ecosystem of specialized technology partners that improve consistency, reduce operational variability, and support more predictable biologics development from molecular design through laboratory execution. "Reliable gene synthesis is foundational to accelerating biologics development," said Jason T. Gammack, Chief Executive Officer of Ansa Biotechnologies. "Our mission is to eliminate uncertainty at one of the earliest stages of the workflow so researchers can move forward with confidence. We're proud to support Axio BioPharma and its Forge platform as they continue helping customers bring antibody programs from sequence to purified material with greater speed and predictability." As demand for faster biologics development continues to increase, partnerships that strengthen critical upstream workflows are becoming increasingly important. By combining Axio Forge's high-throughput antibody production capabilities with Ansa's enzymatic DNA synthesis technology, the companies are helping to provide researchers with a more reliable foundation for antibody discovery while reducing one of the most common sources of schedule risk early in development. About Axio BioPharma Axio BioPharma is a vendor-neutral data infrastructure company for biomanufacturing. Axio Lattice is a coordination and translation layer that lets pharma sponsors and their manufacturing partners work from the same process data across organizational boundaries, without moving data or changing ownership. Axio Forge is a high-throughput non-GMP antibody lab producing research-grade monoclonal antibodies on a 3-5 week turnaround. Axio is headquartered in Madison, Wisconsin. Media Contact Madelyn De Los Santos Putnam Insights [email protected] Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. 50 States Today do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Ansa Biotechnologies to showcase Breakthrough DNA Synthesis Technology backed by industry's only On-Time Guarantee at SynBioBeta 2026 conference. Direct, sequence-perfect clonal DNA up to 50 kb is empowering customers to expand their design space and innovate without compromise EMERYVILLE, Calif.-(BUSINESS WIRE)-#50kb - Ansa Biotechnologies, Inc., the trusted partner for DNA synthesis, today announced its lineup of presentations at the upcoming SynBioBeta 2026 conference, taking place May 4-7 in San Jose, Calif. The annual event brings together leading innovators, investors, engineers, and entrepreneurs who are advancing the future of synthetic biology. Conference attendees are invited to meet Ansa's leadership team and hear directly from customers at booth 312. Spanning 100 bp to 50 kb, Ansa's direct, sequence-perfect clonal DNA products deliver unmatched quality, ultra-fast turnaround times as short as 11 business days, market-changing pricing starting at $0.13 per base pair, and the industry's only on-time, complete order shipment guarantee. The products are enabling researchers to design and assemble longer, more complex constructs for next-generation cell and gene therapies, genome engineering, bioproduction, vaccine research, and agrigenomics applications. "The SynBioBeta conference is where we engage with one of the most forward-thinking communities shaping the next era of biology, and we are eager to share the latest developments in our push to deliver the most accurate and reliable synthetic DNA," said Jason T. Gammack, CEO of Ansa Biotechnologies. "At this year's conference, our customers will provide firsthand perspectives on their Ansa experience. We believe all scientists should expect to have complete confidence in sequence accuracy and delivery timelines, without trade-offs in sequence length or complexity." Featured Presentations Up and to the Right: A New Era of Innovation Enabled by AI and Complex DNA Main stage on Tuesday, May 5, 2:15 pm PDT Jason T. Gammack, CEO, Ansa Biotechnologies Breaking the Barriers of DNA Synthesis: Shattering the Ceiling Breakout panel on Tuesday, May 5, 3:00 pm PDT Featured participant: Jason T. Gammack Skip the Assembly, Go Straight to Your Next Breakthrough: How Innovative DNA Synthesis Is Changing What's Possible in Biopharma Breakout panel on Wednesday, May 6, 3:30 pm PDT * Christopher Vakulskas, Integrated DNA Technologies * Derek Smith, Gilead Sciences * Colin Harvey, Hexagon Bio * Geoff Hamilton, Ansa Biotechnologies (moderator) The New Biosecurity Frontier: AI, Automation, and the Rise of Biodefense in Programmable Biology Breakout panel on Wednesday, May 6, 3:30 pm PDT Featured participant: Scott Fay, Ansa Biotechnologies Ansa's synthesis platform provides both the length and complexity needed to design and assemble critical DNA constructs at scale. Exclusively manufactured in the United States, Ansa's products integrate seamlessly into existing workflows while empowering the next wave of biological discovery. The company's sustainable approach uses no harsh chemicals, preserving DNA integrity while enabling the synthesis of longer, more complex sequences. Ansa operates under a rigorous biosecurity framework and complies fully with the U.S. Office of Science and Technology Policy Framework for Nucleic Acid Synthesis Screening. For more information about Ansa's products, visit www.ansabio.com/products. About Ansa Biotechnologies Ansa Biotechnologies is redefining DNA synthesis with a bold commitment to quality, customer satisfaction, and success. The Ansa On-Time Guarantee is simple and clear: your complete order on time or it's free. This unprecedented level of service reliability and predictability is made possible by Ansa's dedicated team of experts and proprietary enzymatic synthesis platform, which can rapidly and accurately produce even the highly complex DNA elements that challenge legacy approaches. Products are delivered as sequence-perfect clonal DNA or sequence-verified linear double-stranded DNA fragments. Headquartered in Emeryville, CA, Ansa is empowering a global community of scientists to accelerate breakthroughs in healthcare, life sciences, and other industries powered by synthetic DNA. Discover more at ansabio.com or follow the company on X, Bluesky, and LinkedIn. Ansa Biotechnologies and the Ansa Biotechnologies logo are trademarks of Ansa Biotechnologies, Inc.
Ansa Biotechnologies has appointed Matthias Arenskötter as chief operating officer to lead global operations as the company scales its synthetic DNA production. Dr Arenskötter will oversee manufacturing, supply chain and quality systems to meet rising demand for Ansa's enzymatic DNA synthesis platform. Dr Arenskötter brings nearly 20 years of operational leadership in DNA synthesis and life sciences. He previously spent over 19 years at GeneArt, Life Technologies and Thermo Fisher Scientific, where he built gene synthesis manufacturing operations and led qPCR assay production expansion during the COVID-19 pandemic. The Emeryville, California-based company manufactures synthetic DNA exclusively in the United States using a chemical-free enzymatic process that enables longer, more complex sequences than traditional methods.
Ansa Biotechnologies appoints Matthias Arenskötter as chief operating officer. March 30, 2026 Seasoned DNA synthesis executive will oversee expansion of production capacity to meet rising demand for high-quality long and complex DNA products backed by industry's only service guarantee EMERYVILLE, Calif. - March 31, 2026 - Ansa Biotechnologies Inc., the trusted partner for DNA synthesis, today announced the appointment of Matthias Arenskötter, PhD, as chief operating officer. Dr. Arenskötter will lead global operations, including manufacturing, supply chain, and quality systems, as the company scales to meet rapidly rising demand for its groundbreaking synthetic DNA products. Dr. Arenskötter brings almost two decades of operational leadership experience across high-growth DNA synthesis and life sciences organizations. He has a proven track record of scaling complex platforms and optimizing advanced manufacturing systems. At Ansa, he will play a pivotal role in expanding production capacity, enhancing operational efficiency, and supporting customer adoption across the biotechnology, synthetic biology, and pharmaceutical sectors. "Matthias has a clear passion for empowering scientists and has deep experience in gene synthesis, having spent close to 20 years manufacturing DNA and RNA for leading organizations," said Jason T. Gammack, CEO of Ansa Biotechnologies. "His leadership will be instrumental in strengthening our operational foundation, advancing our commercialization strategy, and positioning Ansa for long-term market leadership." Prior to joining Ansa, Dr. Arenskötter spent more than 19 years at GeneArt, Life Technologies, and Thermo Fisher Scientific, where he held senior roles across manufacturing and manufacturing engineering for global operations. During his tenure, he built and scaled gene synthesis manufacturing operations for the US market and led the rapid expansion of qPCR assay production during the COVID-19 pandemic. He also helped scale the company's digital manufacturing execution system infrastructure and led operations for numerous new product implementations. Dr. Arenskötter holds a PhD in microbiology from the University of Münster. "I am thrilled to join Ansa at such an exciting time in the company's development and in the gene synthesis field more broadly, as the need for longer and more complex DNA is more apparent than ever," said Dr. Arenskötter. "Ansa's proprietary enzymatic DNA synthesis platform and transparent, customer-first approach are redefining industry expectations by decoupling DNA synthesis from its decades-long manufacturing constraints. I look forward to working with the team to scale operations, elevate the customer experience, and enable the next wave of breakthroughs across cell and gene therapy, genome engineering, bioproduction, and advanced biologics." Ansa's synthesis platform provides both the length and complexity needed to design and assemble critical DNA constructs at scale. Exclusively manufactured in the United States, Ansa's products integrate seamlessly into existing workflows while empowering the next wave of biological discovery. The company's sustainable approach uses no harsh chemicals, preserving DNA integrity while enabling the synthesis of longer, more complex sequences. Ansa is guided by a rigorous biosecurity framework and full compliance with the U.S. Office of Science and Technology Policy Framework for Nucleic Acid Synthesis Screening. For more information about Ansa's products, visit www.ansabio.com/products. About Ansa Biotechnologies Ansa Biotechnologies is redefining DNA synthesis with a bold commitment to quality, customer satisfaction, and success. The Ansa On-Time Guarantee is simple and straightforward: your complete order on time or it's free. This unprecedented level of service reliability and predictability is made possible by Ansa's dedicated team of experts and proprietary enzymatic synthesis platform, which can rapidly and accurately produce even the highly complex DNA elements that stymie legacy approaches. Products are delivered as sequence-perfect clonal DNA or sequence-verified linear double-stranded DNA fragments. Headquartered in Emeryville, Calif., Ansa is empowering a global community of scientists to accelerate breakthroughs in healthcare, life sciences, and other industries powered by synthetic DNA. Discover more at ansabio.com or follow the company on X, Bluesky, and LinkedIn. Ansa Biotechnologies and the Ansa Biotechnologies logo are trademarks of Ansa Biotechnologies, Inc.
Integrated DNA Technologies expands synthetic biology portfolio with Ansa Biotechnologies' Clonal DNA and XL Clonal DNA products. New collaboration empowers customers with sequence-perfect constructs as long as 50 kb SUNNYVALE and EMERYVILLE, Calif. - Jan. 14, 2026 - Integrated DNA Technologies (IDT), a Danaher company and a global leader in genomics, and Ansa Biotechnologies, Inc., a trusted partner for DNA synthesis, today announced a strategic collaboration that adds new complementary capabilities to IDT's synthetic biology portfolio. Ansa's Clonal DNA and XL Clonal DNA products, ranging from 100 bp to 50 kb, will be made available to IDT customers, enabling researchers to design and assemble longer, more complex constructs for next-generation cell and gene therapy discovery, vaccine research, and agrigenomics applications. By joining forces, IDT will pair its nearly 40-year legacy of quality and service, as well as its global presence, with Ansa's breakthrough enzymatic DNA synthesis platform to accelerate the delivery of challenging motifs, higher complexity, and longer constructs. The partnership prioritizes the delivery of a new standard for speed, precision, and reliability. Each sequence is rigorously verified and optimized for GC content, homopolymers, and repetitive elements to give researchers confidence that their designs are accurate, which helps to minimize rework, troubleshooting, and downstream risk. "Customers face unprecedented complexity in their research, and they deserve solutions that make progress simpler and faster," said IDT President Ajay Gannerkote. "IDT's partnership with Ansa reflects the combination of proven reliability and trust with innovation in synthetic biology to deliver exactly that. This collaboration will help ensure researchers can come to IDT for their needs across every dimension of complexity, enabling breakthroughs that truly matter." Jason T. Gammack, Chief Executive Officer of Ansa, commented: "Ansa was founded to solve the hardest problems in DNA synthesis: length, complexity, and reliability. Through our collaboration with IDT, we are dismantling long-standing technical barriers and enabling more researchers worldwide to push the boundaries of science with greater confidence and without compromise." Ansa is redefining what is possible in synthetic biology through its proprietary enzymatic platform, which provides both the length and complexity needed to design and assemble critical DNA constructs at scale. Ansa's sustainable approach uses no harsh chemicals, preserving DNA integrity while enabling the synthesis of longer, more complex sequences. Exclusively manufactured in the United States, Ansa's DNA products integrate seamlessly into existing workflows while empowering the next wave of biological discovery. The company is guided by a rigorous biosecurity framework and full compliance with the U.S. Office of Science and Technology Policy Framework for Nucleic Acid Synthesis Screening. IDT customers can purchase Ansa Clonal DNA and XL Clonal DNA products at www.idtdna.com/complexDNA. Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. Bio-IT World Inc work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Its vision of enabling researchers to rapidly move from the lab to life-changing advances reflects its ongoing commitment to a healthier, brighter future for all. IDT is proud to be part of Danaher, a global science and technology leader. Visit www.Danaher.com to learn more about Danaher, a leading life sciences and diagnostics innovator committed to accelerating the power of science and technology to improve human health. For more information about IDT, visit www.idtdna.com and follow the company on LinkedIn, X,, YouTube, Instagram and Bluesky. Disclaimer: RUO - For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations. About Ansa Biotechnologies Ansa Biotechnologies is redefining DNA synthesis with a bold commitment to quality, customer satisfaction, and success. The Ansa On-Time Guarantee is simple and straightforward: your complete order on time or it's free. This unprecedented level of service reliability and predictability is made possible by Ansa's dedicated team of experts and proprietary enzymatic synthesis platform, which can rapidly and accurately produce even the highly complex DNA elements that stymie legacy approaches. Products are delivered as sequence-perfect clonal DNA or sequence-verified linear double-stranded DNA fragments. Headquartered in Emeryville, Calif., Ansa is empowering a global community of scientists to accelerate breakthroughs in healthcare, life sciences, and other industries powered by synthetic DNA. Discover more at ansabio.com or follow the company on X, Bluesky, and LinkedIn. Ansa Biotechnologies and the Ansa Biotechnologies logo are trademarks of Ansa Biotechnologies, Inc.